Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Expands By 22.0%

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 160,347 shares, an increase of 22.0% from the December 31st total of 131,425 shares. Based on an average daily trading volume, of 101,779 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.6% of the shares of the company are sold short. Currently, 1.6% of the shares of the company are sold short. Based on an average daily trading volume, of 101,779 shares, the days-to-cover ratio is currently 1.6 days.

Insider Activity at Cocrystal Pharma

In other Cocrystal Pharma news, Director Phillip Md Et Al Frost purchased 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was acquired at an average cost of $0.95 per share, with a total value of $47,500.00. Following the acquisition, the director owned 1,838,551 shares of the company’s stock, valued at approximately $1,746,623.45. This represents a 2.80% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 159,000 shares of company stock valued at $152,710. Insiders own 28.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cocrystal Pharma presently has an average rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Price Performance

NASDAQ:COCP remained flat at $0.98 during mid-day trading on Tuesday. 40,134 shares of the company traded hands, compared to its average volume of 87,904. The stock’s 50 day moving average is $1.03 and its 200 day moving average is $1.23. Cocrystal Pharma has a 12-month low of $0.90 and a 12-month high of $2.67. The stock has a market capitalization of $13.51 million, a PE ratio of -1.04 and a beta of 1.13.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.03. Equities research analysts anticipate that Cocrystal Pharma will post -1.85 EPS for the current year.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.